Pharmacological evaluation of the scid t cell transfer model of colitis: As a model of Crohn's disease

International Journal of Inflammation

Volumn 2012, Issue , 2012, Pages

  Lindebo Holm, Thomas ^a   Poulsen, Steen Seier ^b   Markholst, Helle ^a   Reedtz Runge, Stine ^a  

^a NOVO NORDISK A S   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ALPHA4BETA7 INTEGRIN ANTIBODY; CYCLOSPORIN; CYCLOSPORIN A; ENROFLOXACIN; ETANERCEPT; IMMUNOMODULATING AGENT; INTERLEUKIN 12P40 ANTIBODY; INTERLEUKIN 6 ANTIBODY; METRONIDAZOLE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CONTROLLED STUDY; CROHN DISEASE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HISTOLOGY; MONITORING; MOUSE; NONHUMAN; PRIORITY JOURNAL; REMISSION; SCID MOUSE;

EID: 84876510668     PISSN: 20908040     EISSN: 20420099     Source Type: Journal    
DOI: 10.1155/2012/412178     Document Type: Article

References (50)

1. Loftus J., Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004 126 6 1504 1517 2-s2.0-2442563304 10.1053/j.gastro.2004.01.063 (Pubitemid 38649869)
2. Casellas F., López-Vivancos J., Badia X., Vilaseca J., Malagelada J. R., Influence of inflammatory bowel disease on different dimensions of quality of life. European Journal of Gastroenterology and Hepatology 2001 13 5 567 572 2-s2.0-0034997699 10.1097/00042737-200105000-00017 (Pubitemid 32466261)
3. Bouma G., Strober W., The immunological and genetic basis of inflammatory bowel disease. Nature Reviews Immunology 2003 3 7 521 533 2-s2.0-0142053206 10.1038/nri1132 (Pubitemid 37328672)
4. Dryden G. W., Overview of biologic therapy for Crohn's disease. Expert Opinion on Biological Therapy 2009 9 8 967 974 2-s2.0-67650663268 10.1517/14712590903048909
5. Sandborn W. J., Feagan B. G., Fedorak R. N., Scherl E., Fleisher M. R., Katz S., Johanns J., Blank M., Rutgeerts P., A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008 135 4 1130 1141 2-s2.0-53049091561 10.1053/j.gastro.2008.07.014
6. Bilsborough J., Viney J. L., From model to mechanism: lessons of mice and men in the discovery of protein biologicals for the treatment of inflammatory bowel disease. Expert Opinion on Drug Discovery 2006 1 1 69 83 10.1517/17460441.1.1.69
7. Baumgart D. C., Sandborn W. J., Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007 369 9573 1641 1657 2-s2.0-34248136340 10.1016/S0140-6736(07)60751-X (Pubitemid 46722637)
8. Strober W., Fuss I. J., Blumberg R. S., The immunology of mucosal models of inflammation. Annual Review of Immunology 2002 20 495 549 2-s2.0-0036218221 10.1146/annurev.immunol.20.100301.064816 (Pubitemid 34293433)
9. + T cells. Journal of Experimental Medicine 1993 178 1 237 244 2-s2.0-0027163182 (Pubitemid 23173259)
10. + T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. International Immunology 1993 5 11 1461 1471 2-s2.0-0027517545 (Pubitemid 23325202)
11. + T cells. Immunity 1994 1 7 553 562 2-s2.0-0028519015
12. Hue S., Maloy K. J., McKensie B., Cua D., Powrie F., IL-23 and not IL-12 is essential for the development of IBD. Inflammatory Bowel Diseases 2006 12 supplement 2 S25
13. Uhlig H. H., Powrie F., Mouse models of intestinal inflammation as tools to understand the pathogenesis of inflammatory bowel disease. European Journal of Immunology 2009 39 8 2021 2026 2-s2.0-70249137267 10.1002/eji.200939602
14. Coombes J. L., Robinson N. J., Maloy K. J., Uhlig H. H., Powrie F., Regulatory T cells and intestinal homeostasis. Immunological Reviews 2005 204 184 194 2-s2.0-16244379546 10.1111/j.0105-2896.2005.00250.x (Pubitemid 40460502)
15. - T cells leads to rapid colitis: an improved model for pharmacologic testing. International Immunopharmacology 2006 6 8 1341 1354 2-s2.0-33744968175 10.1016/j.intimp.2006.04.017 (Pubitemid 43868195)
16. Yen D., Cheung J., Scheerens H., Poulet F., McClanahan T., Mckenzie B., Kleinschek M. A., Owyang A., Mattson J., Blumenschein W., Murphy E., Sathe M., Cua D. J., Kastelein R. A., Rennick D., IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. Journal of Clinical Investigation 2006 116 5 1310 1316 2-s2.0-33646397611 10.1172/JCI21404
17. + T cell response by targeting lymphatic recruitment of APC. Journal of Immunology 2009 182 4 2425 2431 2-s2.0-61449144436 10.4049/jimmunol.0803661
18. 7 prevents and ameliorates immunization-induced colitis in IL-2(-/-) mice. Journal of Immunology 1999 162 8 4975 4982 (Pubitemid 29314905)
19. Melgar S., Karlsson L., Rehnstrom E., Karlsson A., Utkovic H., Jansson L., Michaëlsson E., Validation of murine dextran sulfate sodium-induced colitis using four therapeutic agents for human inflammatory bowel disease. International Immunopharmacology 2008 8 6 836 844 2-s2.0-43049135132 10.1016/j.intimp.2008.01.036
20. Davidson N. J., Hudak S. A., Lesley R. E., Menon S., Leach M. W., Rennick D. M., IL-12, but not IFN- γ plays a major role in sustaining the chronic phase of colitis in IL-10-deficient mice. Journal of Immunology 1998 161 6 3143 3149 2-s2.0-0032530697 (Pubitemid 28425743)
21. Kim J., Chang C. K., Hayden T., Liu F. C., Benjamin J., Hamerman J. A., Lanier L. L., Kang S. M., The activating immunoreceptor NKG2D and its ligands are involved in allograft transplant rejection. Journal of Immunology 2007 179 10 6416 6420 2-s2.0-38449113206
22. Plessner H. L., Lin P. L., Konno T., Louie J. S., Kirschner D., Chan J., Flynn J. L., Neutralization of Tumor Necrosis Factor (TNF) by antibody but not TNF receptor fusion molecule exacerbates chronic murine tuberculosis. Journal of Infectious Diseases 2007 195 11 1643 1650 2-s2.0-34249007153 10.1086/517519 (Pubitemid 46799222)
23. Kang S. S., Bloom S. M., Norian L. A., Geske M. J., Flavell R. A., Stappenbeck T. S., Allen P. M., An antibiotic-responsive mouse model of fulminant ulcerative colitis. PLoS Medicine 2008 5 3, article e41 2-s2.0-41549111071 10.1371/journal.pmed.0050041 (Pubitemid 351471693)
24. Williams K. L., Fuller C. R., Dieleman L. A., DaCosta C. M., Haldeman K. M., Sartor R. B., Lund P. K., Enhanced survival and mucosal repair after dextran sodium sulfate-induced colitis in transgenic mice that overexpress growth hormone. Gastroenterology 2001 120 4 925 937 2-s2.0-0035123651 (Pubitemid 32193189)
25. Sanchez-Muñoz F., Dominguez-Lopez A., Yamamoto-Furusho J. K., Role of cytokines in inflammatory bowel disease. World Journal of Gastroenterology 2008 14 27 4280 4288 2-s2.0-55949086652 10.3748/wjg.14.4280
26. + macrophages. Gastroenterology 2011 141 6 1026 1038
27. Sandborn W. J., Hanauer S. B., Katz S., Safdi M., Wolf D. G., Baerg R. D., Tremaine W. J., Johnson T., Diehl N. N., Zinsmeister A. R., Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001 121 5 1088 1094 2-s2.0-0034754477 (Pubitemid 33022088)
28. Trinchieri G., Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nature Reviews Immunology 2003 3 2 133 146 2-s2.0-0037313578 10.1038/nri1001 (Pubitemid 37328691)
29. Liu Z., Geboes K., Heremans H., Overbergh L., Mathieu C., Rutgeerts P., Ceuppens J. L., Role of interleukin-12 in the induction of mucosal inflammation and abrogation of regulatory T cell function in chronic experimental colitis. European Journal of Immunology 2001 31 5 1550 1560 2-s2.0-0034998259 10.1002/1521-4141(200105)31:51550::AID-IMMU1550>3.0.CO;2-3 (Pubitemid 32454704)
30. Neurath M. F., IL-23: a master regulator in Crohn disease. Nature Medicine 2007 13 1 26 28 2-s2.0-33846036986 10.1038/nm0107-26 (Pubitemid 46067378)
31. Mannon P. J., Fuss I. J., Mayer L., Elson C. O., Sandborn W. J., Present D., Dolin B., Goodman N., Groden C., Hornung R. L., Quezado M., Neurath M. F., Salfeld J., Veldman G. M., Schwertschlag U., Strober W., Anti-interleukin-12 antibody for active Crohn's disease. New England Journal of Medicine 2004 351 20 2069 2079 2-s2.0-8344284998 10.1056/NEJMoa033402 (Pubitemid 39482500)
32. Yamamoto M., Yoshizaki K., Kishimoto T., Ito H., IL-6 is required for the development of Th1 cell-mediated murine colitis. Journal of Immunology 2000 164 9 4878 4882 2-s2.0-0034193039 (Pubitemid 30238092)
33. Atreya R., Mudter J., Finotto S., Müllberg J., Jostock T., Wirtz S., Schütz M., Bartsch B., Holtmann M., Becker C., Strand D., Czaja J., Schlaak J. F., Lehr H. A., Autschbach F., Schürmann G., Nishimoto N., Yoshizaki K., Ito H., Kishimoto T., Galle P. R., Rose-John S., Neurath M. F., Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nature Medicine 2000 6 5 583 588 2-s2.0-18344410191 10.1038/75068 (Pubitemid 30305911)
34. -mediated costimulation. Immunological Reviews 2009 229 1 307 321 2-s2.0-65349185047 10.1111/j.1600-065X.2009.00780.x
35. + T cells correlates with suppression of psoriasis and colitis. International Immunopharmacology 2002 2 5 653 672 2-s2.0-18344391018 10.1016/S1567-5769(01) 00201-6 (Pubitemid 34246366)
36. + T cells. Journal of Immunology 1997 158 5 2099 2106 2-s2.0-0031092633 (Pubitemid 127469991)
37. Wirtz S., Neurath M. F., Animal models of intestinal inflammation: new insights into the molecular pathogenesis and immunotherapy of inflammatory bowel disease. International Journal of Colorectal Disease 2000 15 3 144 160 2-s2.0-0033830605 10.1007/s003840000227
38. Feagan B. G., Greenberg G. R., Wild G., Fedorak R. N., Paré P., McDonald J. W. D., Dubé R., Cohen A., Steinhart A. H., Landau S., Aguzzi R. A., Fox I. H., Vandervoort M. K., Treatment of ulcerative colitis with a humanized antibody to the α 4 β 7 integrin. New England Journal of Medicine 2005 352 24 2499 2507 2-s2.0-20444469332 10.1056/NEJMoa042982 (Pubitemid 41007865)
39. Feagan B. G., Greenberg G. R., Wild G., Fedorak R. N., Paré P., McDonald J. W. D., Cohen A., Bitton A., Baker J., Dubé R., Landau S. B., Vandervoort M. K., Parikh A., Treatment of active Crohn's disease with MLN0002, a humanized antibody to the α 4 β 7 integrin. Clinical Gastroenterology and Hepatology 2008 6 12 1370 1377 2-s2.0-57249089077 10.1016/j.cgh.2008.06.007
40. Podolsky D. K., Beyond tumor necrosis factor: next-generation biologic therapy for inflammatory bowel disease. Digestive Diseases 2009 27 3 366 369 2-s2.0-70349919789 10.1159/000228575
41. Cima R. R., Pemberton J. H., Medical and surgical management of chronic ulcerative colitis. Archives of Surgery 2005 140 3 300 310 2-s2.0-16244377146 10.1001/archsurg.140.3.300 (Pubitemid 41001826)
42. McDonald J. W., Feagan B. G., Jewell D., Brynskov J., Stange E. F., Macdonald J. K., Cyclosporine for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2005 2 CD000297 CD002005 2-s2.0-21844432703
43. Ikenoue Y., Tagami T., Murata M., Development and validation of a novel IL-10 deficient cell transfer model for colitis. International Immunopharmacology 2005 5 6 993 1006 2-s2.0-17044392529 10.1016/j.intimp.2005. 01.009
44. Murthy S. N., Cooper H. S., Shim H., Shah R. S., Ibrahim S. A., Sedergran D. J., Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin. Digestive Diseases and Sciences 1993 38 9 1722 1734 2-s2.0-0027275654 (Pubitemid 23271431)
45. Pereira G. M., Miller J. F., Shevach E. M., Mechanism of action of cyclosporine A in vivo. II. T cell priming in vivo to alloantigen can be mediated by an IL-2-independent cyclosporine A-resistant pathway. Journal of Immunology 1990 144 6 2109 2116 2-s2.0-0025213285 (Pubitemid 20106547)
46. Motta I., Colle J. H., Shidani B., Truffa-Bachi P., Interleukin 2/interleukin 4-independent T helper cell generation during an in vitro antigenic stimulation of mouse spleen cells in the presence of cyclosporin A. European Journal of Immunology 1991 21 3 551 557 2-s2.0-0026064306
47. + T lymphocytes via a cyclosporin A-resistant pathway. Immunology 2001 104 3 299 306 2-s2.0-0035173064 10.1046/j.1365-2567.2001.01296.x (Pubitemid 33064455)
48. Kountouras J., Zavos C., Chatzopoulos D., Immunomodulatory benefits of cyclosporine A in inflammatory bowel disease. Journal of Cellular and Molecular Medicine 2004 8 3 317 328 2-s2.0-20044389090 (Pubitemid 44145495)
49. Mitsuyama K., Sata M., Gut microflora: a new target for therapeutic approaches in inflammatory bowel disease. Expert Opinion on Therapeutic Targets 2008 12 3 301 312 2-s2.0-40949166276 10.1517/14728222.12.3.301 (Pubitemid 351419424)
50. Arndt H., Palitzsch K. D., Grisham M. B., Granger D. N., Metronidazole inhibits leukocyte-endothelial cell adhesion in rat mesenteric venules. Gastroenterology 1994 106 5 1271 1276 2-s2.0-0028354152 (Pubitemid 24129244)